Research programme: epilepsy gene therapy - Neurologix

Drug Profile

Research programme: epilepsy gene therapy - Neurologix

Alternative Names: NLX E201

Latest Information Update: 09 Jun 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Neurologix
  • Class Gene therapies; Neuropeptides
  • Mechanism of Action Neuropeptide Y receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Epilepsy

Most Recent Events

  • 16 Mar 2012 Discontinued - Preclinical for Epilepsy in USA (Intracerebral)
  • 16 Mar 2010 Preclinical development is ongoing in USA
  • 01 Oct 2004 Preclinical trials in Epilepsy in USA (Intracerebral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top